Commonly found in males, hemophilia is an X-linked genetic disorder that results in excessive blood loss during injury, causing fatigue or even death. Those suffering from hemophilia are usually administered plasma-derived clotting factors or recombinant clotting factors in order to reduce the effects of the disease. Even though there is no permanent cure for hemophilia, vendors are concentrating on the development of drugs that provide strong therapeutic benefits. Thanks to the immense amount of research and development activities in this area, the global hemophilia drugs market was valued at 10.3 billion in 2015. According to analysts at Technavio, the market is poised to grow at a CAGR of more than 5% by 2020.
From a geographical perspective, it is the Americas followed by EMEA and APAC that dominate the hemophilia drugs market at the global level. Some of the top vendors in this market, as identified by analysts at Technavio, include:
Baxalta
A leading biopharmaceutical company, Baxalta concentrates wholly on the development of therapies for the treatment of hemophilia, immunology, and oncology. Now a part of Shire Pharmaceuticals, hemophilia drugs account for 59% of the total revenue generated by Baxalta in 2015. The company manufactures products across 29 countries and sells them in over 100 countries. At present, it has a market presence in Europe (including Eastern and Central Europe), MEA, APAC, Latin America, Canada, and the US. Advate, Rixubis and Vonvendi are some of its major product offerings.
CSL Behring
A global leader in the plasma protein bio therapeutics industry, CSL Behring undertakes research and development activities, and manufactures and markets biotherapies that are used to treat serious and rare conditions. At present, the company has an established presence in the global hemophilia drugs market with a product for the treatment of both hemophilia A and B. Some of its product offerings include Beriate, IDELVION and Berinin P.
Bayer
A German multinational chemical and pharmaceutical company, Bayer focuses on the R&D, production, and sales of drugs, pharmaceuticals, vaccines, antibiotics, and small components for human and animal health worldwide. With products such as Kogenate FS, the company today has a major presence in the global hemophilia drugs market. Bayer plans to strengthen its position in the market with innovative pipeline candidates such as BAY 949027 (damoctocog alfa pegol) and the anti-TFPI antibody.
Novo Nordisk
A Danish multinational pharmaceutical company, Novo Nordisk provides pharmaceutical products and services for diabetes, hemophilia, obesity, and growth disorders. NovoEight and NovoSeven are its major offerings for hemophilia. With the goal of achieving leadership in both hemophilia A and B markets, the company has filed for the approval of long-acting factor IX in the EU in January 2016.
Pfizer
Pfizer manufactures pharmaceutical products for arthritis, cardiovascular, metabolic, infectious, and respiratory therapy areas. With products such as ReFacto AF/XYNTHA and BeneFIX, Pfizer has emerged as one of the major vendors in the global market for hemophilia drugs. The company has a substantial focus on collaborating and acquiring other players to improve its market share. It has collaborated with Spark Therapeutics for the development of hemophilia drugs.
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is leading the translation of RNAi as a new class of innovative medicines, with a core focus on RNAi therapeutics toward genetically defined targets for the treatment of serious, life-threatening diseases with limited treatment options for patients and their caregivers. Fitusiran (ALN-AT3) is its major product offering for hemophilia.
Biogen
Biogen is an American multinational biotechnology company that develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders. Some of its popular products include ELOCTATE and ALPROLIX.
Emergent BioSolutions
Emergent BioSolutions is a multinational specialty biopharmaceutical company that develops, manufactures, and delivers a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. The company develops vaccines and antibody therapeutics to address medical needs and emerging health threats.
Dimension Therapeutics
Dimension Therapeutics is a gene therapy company focused on developing novel treatments for rare diseases. The company is focused on advancing its platform of gene therapy programs in rare diseases through clinical development, starting with lead programs in hemophilia, and building out a world-class product engine for adeno-associated virus (AAV) therapeutics. DTX101 AAVrh10 FIX and DTX201 AAV FVIII are its major product offerings.
Catalyst Biosciences
Catalyst Biosciences focuses on developing novel medicines to address serious medical conditions by using a scientific approach centred on protease-based therapeutic candidates to build a clinical-stage biopharmaceutical company whose current mission is to develop valuable therapies for patients with hemophilia. It has developed catalytic biopharmaceutical products using engineered human proteases. CB 2679d/Isu 304 is its product offering for hemophilia.
Want to find out where the hemophilia drugs market is headed in the next few years?
Order the 2016-2020 Report on the Global Hemophilia Drugs Market
